10 / 43
10
EXTREME: estándar de tratamiento en 1ªL de CCC R/M
•
1. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers V1 2016
•
2. Grégoire V et al. Ann Oncol 2010;21 (Suppl 5):v184‒6
•
3. Vermorken JB, et al. N Engl J Med 2008;359:1116–27
•
4. Peyrade F, et al. Oral Oncology 2013;49:482–91
•
*European Cooperative Oncology Group (ECOG) performance status
•
EXTREME: ERBITUX in first-line Treatment of REcurrent or MEtastatic head and
neck cancer
Performance status*
Recommendations for treatment of 1
st
line R/M SCCHN
4
0–1
Cetuximab + cisplatin/carboplatin + 5-FU followed by cetuximab monotherapy maintenance
(EXTREME regimen)
2
EXTREME regimen can be given if tolerated
Single-agent CT
3
Best supportive care, not eligible for clinical trials
The standard of care for R/M SCCHN is considered to be the regimen from the EXTREME trial of cetuximab + cisplatin or carboplatin + 5-
FU (
Category 1 recommendation
)
1
NCCN Clinical Practice Guidelines
“1
st
line option for fit patients should include the combination of cetuximab with cisplatin or carboplatin plus 5-FU (
Grade II, A
recommendation
)”
2
EHNS-ESMO-ESTRO Clinical Practice Guidelines